Quoin Pharmaceuticals, Ltd.
QNRX
$6.97
-$0.18-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.96% | 7.23% | 5.06% | 20.05% | 12.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.30% | 29.67% | 87.95% | 59.02% | 77.49% |
| Operating Income | -44.30% | -29.67% | -87.95% | -59.02% | -77.49% |
| Income Before Tax | -45.32% | -31.10% | -88.14% | -68.02% | -87.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.32% | -31.10% | -88.14% | -68.02% | -87.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.32% | -31.10% | -88.14% | -68.02% | -87.23% |
| EBIT | -44.30% | -29.67% | -87.95% | -59.02% | -77.49% |
| EBITDA | -44.59% | -29.86% | -88.87% | -59.60% | -78.41% |
| EPS Basic | 69.83% | 72.85% | 86.57% | 58.79% | 54.07% |
| Normalized Basic EPS | 69.83% | 72.85% | 86.57% | 58.79% | 54.07% |
| EPS Diluted | 69.91% | 73.45% | 86.57% | 59.15% | 53.95% |
| Normalized Diluted EPS | 69.83% | 72.85% | 86.57% | 58.79% | 54.07% |
| Average Basic Shares Outstanding | 381.62% | 382.86% | 1,300.51% | 307.62% | 307.62% |
| Average Diluted Shares Outstanding | 381.55% | 383.83% | 1,324.00% | 309.76% | 309.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |